Nonradioactive Serotonin Release Assay Compared to Gold Standard
|
By LabMedica International staff writers Posted on 01 Feb 2016 |
The serotonin release assay (SRA) is considered the gold standard laboratory test for heparin-induced thrombocytopenia (HIT) and the classical SRA method uses platelets loaded with radiolabeled serotonin to evaluate platelet activation by HIT immune complexes.
Laboratory tests for HIT consist of immunoassays, usually enzyme-linked immunosorbent assays (ELISAs), and functional platelet activation assays. Immunoassays detect the presence of immunoglobulins that bind heparin: PF4 complexes, while functional tests detect platelet activation by immune complexes consisting of macromolecular aggregates of heparin: PF4 and antibody.
Scientists at the ARUP Laboratories Institute (Salt Lake City, UT, USA) and their colleagues have validated the performance characteristics of a high-performance liquid chromatography (HPLC) SRA method. The team used serum samples stored frozen until the time of evaluation that had been submitted to their laboratory for HIT testing. Reagent platelets were obtained by collecting blood from healthy donors known to be reactive and with no history of HIT, platelet dysfunction, or current nonsteroidal anti-inflammatory drugs (NSAID) use.
Assay setup was automated on a JANUS liquid handling system (PerkinElmer, Waltham, MA, USA), although platelets were pipetted manually. Serotonin released from reagent platelets was quantitated (ng/mL) by HPLC on a gel permeation chromatography (GPC), size exclusion chromatography (SEC), 1260 instrument (Agilent Technologies; Santa Clara, CA, USA) with fluorescent detection (excitation 285 nm, emission 345 nm). Results were expressed as percentage release and classified as positive, negative, or indeterminate based on previously published cutoffs.
The serum samples from 250 subjects with suspected HIT were tested in the HPLC-SRA and with the radioactive method. Concordant classifications were observed in 230 samples (92%). Sera from 41 healthy individuals tested negative. Between-run imprecision studies showed standard deviation of less than 6% release for positive, weak positive and negative serum pools. Stability studies demonstrated stability after two freeze–thaw cycles or up to a week of refrigeration.
The authors concluded that the HPLC-SRA has robust performance characteristics, equivalent to the classic radioactive method, which has long been considered the gold standard assay for HIT. Results from nonradioactive SRA methods using novel serotonin detection methods provide equivalent information to radioactive methods for HIT diagnostic algorithms but avoid the laboratory complexities of working with radioactivity. The HPLC-SRA method has been optimized to accommodate the demands placed on our high-volume reference laboratory by use of an automated dilutor to perform many pipetting steps and laboratory-developed software to perform calculations. The study was published in the February 2016 issue of the International Journal of Laboratory Hematology.
Related Links:
ARUP Laboratories Institute
Perkin Elmer
Agilent Technologies
Laboratory tests for HIT consist of immunoassays, usually enzyme-linked immunosorbent assays (ELISAs), and functional platelet activation assays. Immunoassays detect the presence of immunoglobulins that bind heparin: PF4 complexes, while functional tests detect platelet activation by immune complexes consisting of macromolecular aggregates of heparin: PF4 and antibody.
Scientists at the ARUP Laboratories Institute (Salt Lake City, UT, USA) and their colleagues have validated the performance characteristics of a high-performance liquid chromatography (HPLC) SRA method. The team used serum samples stored frozen until the time of evaluation that had been submitted to their laboratory for HIT testing. Reagent platelets were obtained by collecting blood from healthy donors known to be reactive and with no history of HIT, platelet dysfunction, or current nonsteroidal anti-inflammatory drugs (NSAID) use.
Assay setup was automated on a JANUS liquid handling system (PerkinElmer, Waltham, MA, USA), although platelets were pipetted manually. Serotonin released from reagent platelets was quantitated (ng/mL) by HPLC on a gel permeation chromatography (GPC), size exclusion chromatography (SEC), 1260 instrument (Agilent Technologies; Santa Clara, CA, USA) with fluorescent detection (excitation 285 nm, emission 345 nm). Results were expressed as percentage release and classified as positive, negative, or indeterminate based on previously published cutoffs.
The serum samples from 250 subjects with suspected HIT were tested in the HPLC-SRA and with the radioactive method. Concordant classifications were observed in 230 samples (92%). Sera from 41 healthy individuals tested negative. Between-run imprecision studies showed standard deviation of less than 6% release for positive, weak positive and negative serum pools. Stability studies demonstrated stability after two freeze–thaw cycles or up to a week of refrigeration.
The authors concluded that the HPLC-SRA has robust performance characteristics, equivalent to the classic radioactive method, which has long been considered the gold standard assay for HIT. Results from nonradioactive SRA methods using novel serotonin detection methods provide equivalent information to radioactive methods for HIT diagnostic algorithms but avoid the laboratory complexities of working with radioactivity. The HPLC-SRA method has been optimized to accommodate the demands placed on our high-volume reference laboratory by use of an automated dilutor to perform many pipetting steps and laboratory-developed software to perform calculations. The study was published in the February 2016 issue of the International Journal of Laboratory Hematology.
Related Links:
ARUP Laboratories Institute
Perkin Elmer
Agilent Technologies
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Hematology News
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes

- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








